Shenjiahua,was born in 1965. He Received the Ph.D. degree from Fudan University. He is Principal Investigator, Professor of SIMM. His research interested is new drug R&D of Diabetes, cardiovascular, kidney disease. Since 2000, His research projects have been funded by National Major Science and Technology Program “new drug creation”, “863” Program, the National Basic Research Program of China (973 Program) and National Natural Science Foundation of China. He has made an impressive achievement in anti-diabetic, anti-cardiovascular diseases, anti-polycystic kidney drug discovery. He has published more than 100 original papers (cited more than 1000 times) such as PNAS、JACS etc. He also has applied 32 patents (authorized 20 international patents).His diabetic project has been transferred to international pharmaceutical company, and the kidney project has been transferred to domestic pharmaceutical company. His research results won the National Natural Science Awards (2nd class) in 2007 and Shanghai Science & Technology Progress Award (1st class) in 2003, Shanghai first-class technical professionals.

Education
1995-1998 Doctor degree in physics, Fudan University
1992-1995 Master Degree in Electronic engineering, Xi`an Jiaotong University
1983-1987 Bachelor degree in Materials Science, National University of Defense Technology.

Experience
2004-Now  Shanghai Institute of Materia Medica , Chinese Academy of Sciences Principal Investigator, Professor, PhD Supervisor
2002-2004 Shanghai Institute of Materia Medica , Chinese Academy of Sciences Principal Investigator, Professor
2000-2002 Shanghai Institute of Materia Medica , Chinese Academy of Sciences, Associate Professor
1998-2000 Shanghai Institute of Materia Medica , Chinese Academy of Sciences Postdoctoral
1987-1992 G & A Technologies Co., Ltd. Technician，engineer

1. Discovery and pre-clinical research of polycystic kidney drug
2. Discovery and optimization of new anti-diabetic drug
3. Atherosclerosis Drug Discovery
4. Drug Discovery for Nervous System Diseases

1. National Major Science and Technology Program，The research of new anti-diabetic drug candidate DC250188，Shenjiahua，2008.1-2010.12
2. National Major Science and Technology Program，The new drug research of Lp-PLA2 inhibitors and anti-atherosclerosis，Chenjunhua，2011.1-2015.12
3. International collaboration，Technology transfer and collaboration of new anti-diabetic drug candidate DC250188，Shenjiahua，2009.9-2013.9
4. Business Cooperation，Technology transfer and collaboration of polycystic kidney drug candidate DJ5，Shenjiahua，2013.7-2016.12

1. Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.Wang K, Xu W, Zhang W, Mo M, Wang Y, Shen J. Bioorg Med Chem Lett. 2013 May 15;23(10):2897-901.
2. Design and synthesis of imidazole and triazole derivatives as Lp-PLA？ inhibitors and the unexpected discovery of highly potent quaternary ammonium salts.Wang K, Xu W, Liu Y, Zhang W, Wang W, Shen J, Wang Y. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1187-92.
3. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.Wang WY, Zhang J, Wu WY, Li J, Ma YL, Chen WH, Yan H, Wang K, Xu WW, Shen JH, Wang YP. PLoS One. 2011;6(8):e23425.
4. Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors. Yang H, Shen Y, Chen J, Jiang Q, Leng Y, Shen J. Eur J Med Chem. 2009 Mar;44(3):1167-71.
5. Derivatives of (phenylsulfonamido-methyl)nicotine and (phenylsulfonamido-methyl)thiazole as novel 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: synthesis and biological activities in vitro. Zhang X, Zhou Y, Shen Y, Du LL, Chen JH, Leng Y, Shen JH. Acta Pharmacol Sin. 2009 Sep;30(9):1344-50.
6. Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.Ye YL, Zhou Z, Zou HJ, Shen Y, Xu TF, Tang J, Yin HZ, Chen ML, Leng Y, Shen JH.Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
7. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice. Zhang X, Zhou Z, Yang H, Chen J, Feng Y, Du L, Leng Y, Shen J. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4455-8.
8. Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. Feng Y, Huang SL, Dou W, Zhang S, Chen JH, Shen Y, Shen JH, Leng Y.Br J Pharmacol. 2010 Sep;161(1):113-26.
9. Synthesis and evaluation of piperidine urea derivatives as efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in diabetic ob/ob mice. Zhang L, Chen J, Ning M, Zou Q, Leng Y, Shen J. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2748-52.
10. 4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists. Zou Q, Duan H, Ning M, Liu J, Feng Y, Zhang L, Zhu J, Leng Y, Shen J. Eur J Med Chem. 2014 May 13;82C:1-15.
11. Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold. Zhu J, Ning M, Guo C, Zhang L, Pan G, Leng Y, Shen J. Eur J Med Chem. 2013 Nov;69:55-68.
12. Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists. Zhu J, Ye Y, Ning M, Mándi A, Feng Y, Zou Q, Kurtán T, Leng Y, Shen J. ChemMedChem. 2013 Jul;8(7):1210-23.
13. Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists. Duan H, Ning M, Chen X, Zou Q, Zhang L, Feng Y, Zhang L, Leng Y, Shen J. J Med Chem. 2012 Dec 13;55(23):10475-89.